NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive Appoints Andrew C. Morton as Chief Human Resources Officer

SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022.

Mr. Morton brings more than 25 years of experience in human resources, talent development, employee experience, and diversity and inclusion. As CHRO, Mr. Morton will oversee all human resources aspects of the Company and will report to NuVasive's Chief Executive Officer, Chris Barry.  

"Drew is a fantastic addition as we continue to transform NuVasive. Our people are our greatest asset—and his extensive experience in building and scaling global talent organizations within healthcare and technology industries will support our growth initiatives," said Mr. Barry. "Most importantly, Drew reflects our shared, cultural mindset in The Cheetah Way­­—which is foundational as we create a high-performing, dynamic team. We are thrilled to welcome Drew to the Company."

Most recently, Mr. Morton served as senior vice president, CHRO at Wright Medical, a global orthopedics and surgical solutions company with more than 4,000 employees and agents, where he leveraged his technology and healthcare background to help lead Wright Medical's talent transformation as it adopted a new digital strategy and focus on software and medical technology innovation. Prior to that, he was senior vice president, CHRO at Hanger, a global provider of orthotic and prosthetic products and services with more than 5,000 employees and 800 patient care locations in the United States. Mr. Morton previously held a variety of human resources management positions at Freescale Semiconductor, and spent 14 years at IBM, where he ultimately led the global learning and management development function supporting more than 30,000 managers and executives annually.  

Mr. Morton holds a Bachelor of Science degree in Finance from the University of Colorado Boulder and a Master of Business Administration degree with a Human Resources concentration from Syracuse University.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive has approximately 2,700 employees and operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Cision View original content to download multimedia:

SOURCE NuVasive, Inc.

Investor contact: Juliet C. Cunningham, NuVasive, Inc., 858-210-2129,; Media contact: Michael Farrington, NuVasive, Inc., 858-909-1940,